SCHEMBL10187503

SCHEMBL10187503

C=CCCC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.59
ERCC5 P28715 1/20 0.55
FEN1 P39748 1/20 0.55
POLB P06746 1/20 0.52
PARP10 Q53GL7 1/20 0.50
SRD5A2 P31213 4/20 0.49
RAB9A P51151 2/20 0.48
GAA P10253 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GLA P06280 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
TGM2 P21980 1/20 0.46
NPC1 O15118 1/20 0.46
ALDH1A1 P00352 1/20 0.46
FFAR1 O14842 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19043378 0.85 MMP1 (0.60) MMP1ERCC5FEN1POLBPARP10
SCHEMBL9814634 0.84 MMP1 (0.77) MMP1ERCC5FEN1POLBPARP10
SCHEMBL317112 0.84 MAPT (0.57) POLBRAB9AGAASMN1; SMN2HTT
SCHEMBL11060279 0.83 ERCC5 (0.58) MMP1ERCC5FEN1POLBPARP10
SCHEMBL27871457 0.81 SMN1; SMN2 (0.62) ERCC5FEN1SRD5A2RAB9AGAA
SCHEMBL27343327 0.81 MMP1 (0.64) MMP1ERCC5FEN1POLBPARP10
SCHEMBL19317521 0.81 MMP1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL19317520 0.81 MMP1 (0.68) MMP1ERCC5FEN1POLBPARP10
SCHEMBL15346436 0.80 MAPT (0.60) MMP1POLBRAB9AHTTL3MBTL1
SCHEMBL19317524 0.80 L3MBTL1 (0.68) MMP1ERCC5FEN1POLBPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093287-B2 Inhibitors of matrix metalloproteinases UNIVERSITY OF NOTRE DAME DU LAC (US) 2012-01-10 US disclosed
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES NOTRE DAME UNIVERSITY (US) 2011-09-15 US disclosed
US-7928127-B2 Inhibitors of matrix metallaproteinases NOTRE DAME UNIVERSITY (US) 2011-04-19 US disclosed
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005420-A1 Inhibitors of Matrix Metallaproteinases MMP9, MMP1, MMP2 MMP1 2/4885ERCC5 2566/4885FEN1 1706/4885
US-20110224275-A1 INHIBITORS OF MATRIX METALLOPROTEINASES MMP9, MMP1, MMP2 MMP1 2/4885ERCC5 1437/4885FEN1 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.